SAN DIEGO , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage , chief executive officer, will present at the BMO 2018 Prescriptions for Success Healthcare Conference in New York City on Wednesday, December 12, 2018 at 9:20 a.m. ET .
PDUFA date set for June 30, 2019 SAN DIEGO , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review the New Drug Application (NDA) for a new formulation of Thiola (tiopronin) in the treatment of
SAN DIEGO , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 4:40 p.m. GMT ( 11:40 a.m. ET ).
Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million convertible senior notes due 2025 SAN DIEGO, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc.
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced new positive data from the ongoing
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018 SAN DIEGO , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Journal of the American Society of Nephrology (JASN) has published online (doi: 10.1681/ASN.2018010091 ) the
SAN DIEGO , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2018 financial results on Thursday, November 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
SAN DIEGO , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018.
SAN DIEGO , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), the patient and
SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced two upcoming presentations related to its development program for sparsentan in the treatment of IgA nephropathy (IgAN), a rare kidney disorder often resulting in end-stage renal disease, during the 15 th
